Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium-223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 20 Dec 2023 Planned End Date changed from 10 Oct 2025 to 1 Sep 2025.
- 21 Jun 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Apr 2023 Planned primary completion date changed from 8 Dec 2023 to 18 Dec 2023.